Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 135

1.

Chemopreventive efficacy of the cyclooxygenase-2 (Cox-2) inhibitor, celecoxib, is predicted by adenoma expression of Cox-2 and 15-PGDH.

Wang J, Cho NL, Zauber AG, Hsu M, Dawson D, Srivastava A, Mitchell-Richards KA, Markowitz SD, Bertagnolli MM.

Cancer Epidemiol Biomarkers Prev. 2018 May 16. pii: cebp.0573.2017. doi: 10.1158/1055-9965.EPI-17-0573. [Epub ahead of print]

PMID:
29769213
2.

Prediction of morbidity following cytoreductive surgery for metastatic gastrointestinal stromal tumour in patients on tyrosine kinase inhibitor therapy.

Fairweather M, Cavnar MJ, Li GZ, Bertagnolli MM, DeMatteo RP, Raut CP.

Br J Surg. 2018 May;105(6):743-750. doi: 10.1002/bjs.10774. Epub 2018 Mar 26.

PMID:
29579329
3.

Sorafenib inhibits proliferation and invasion in desmoid-derived cells by targeting Ras/MEK/ERK and PI3K/Akt/mTOR pathways.

Rosenberg L, Yoon CH, Sharma G, Bertagnolli MM, Cho NL.

Carcinogenesis. 2018 May 3;39(5):681-688. doi: 10.1093/carcin/bgy038.

PMID:
29538717
4.

Amputation for Extremity Sarcoma: Contemporary Indications and Outcomes.

Erstad DJ, Ready J, Abraham J, Ferrone ML, Bertagnolli MM, Baldini EH, Raut CP.

Ann Surg Oncol. 2018 Feb;25(2):394-403. doi: 10.1245/s10434-017-6240-5. Epub 2017 Nov 22.

PMID:
29168103
5.

Surgical Management of Primary Retroperitoneal Sarcomas: Rationale for Selective Organ Resection.

Fairweather M, Wang J, Jo VY, Baldini EH, Bertagnolli MM, Raut CP.

Ann Surg Oncol. 2018 Jan;25(1):98-106. doi: 10.1245/s10434-017-6136-4. Epub 2017 Oct 24.

PMID:
29067605
6.

Fibromatosis of the Breast: Diagnostic Accuracy of Core Needle Biopsy.

Kuba MG, Lester SC, Giess CS, Bertagnolli MM, Wieczorek TJ, Brock JE.

Am J Clin Pathol. 2017 Sep 1;148(3):243-250. doi: 10.1093/ajcp/aqx065.

PMID:
28821190
7.

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.

Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB 3rd, Mulkerin DL, Mayer RJ, Blanke C.

JAMA. 2017 Jun 20;317(23):2392-2401. doi: 10.1001/jama.2017.7105.

8.

Insulin resistance in vascular endothelial cells promotes intestinal tumour formation.

Wang X, Häring MF, Rathjen T, Lockhart SM, Sørensen D, Ussar S, Rasmussen LM, Bertagnolli MM, Kahn CR, Rask-Madsen C.

Oncogene. 2017 Aug 31;36(35):4987-4996. doi: 10.1038/onc.2017.107. Epub 2017 May 1.

9.

Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase Inhibitors: A 2-institutional Analysis.

Fairweather M, Balachandran VP, Li GZ, Bertagnolli MM, Antonescu C, Tap W, Singer S, DeMatteo RP, Raut CP.

Ann Surg. 2017 Apr 26. doi: 10.1097/SLA.0000000000002281. [Epub ahead of print]

PMID:
28448384
10.

Advantages of a Truly Open-Access Data-Sharing Model.

Bertagnolli MM, Sartor O, Chabner BA, Rothenberg ML, Khozin S, Hugh-Jones C, Reese DM, Murphy MJ.

N Engl J Med. 2017 Mar 23;376(12):1178-1181. doi: 10.1056/NEJMsb1702054. No abstract available.

11.

Predicted vitamin D status and colon cancer recurrence and mortality in CALGB 89803 (Alliance).

Fuchs MA, Yuan C, Sato K, Niedzwiecki D, Ye X, Saltz LB, Mayer RJ, Mowat RB, Whittom R, Hantel A, Benson A, Atienza D, Messino M, Kindler H, Venook A, Innocenti F, Warren RS, Bertagnolli MM, Ogino S, Giovannucci EL, Horvath E, Meyerhardt JA, Ng K.

Ann Oncol. 2017 Jun 1;28(6):1359-1367. doi: 10.1093/annonc/mdx109.

PMID:
28327908
12.

Cutaneous Radiation-associated Breast Angiosarcoma: Radicality of Surgery Impacts Survival.

Li GZ, Fairweather M, Wang J, Orgill DP, Bertagnolli MM, Raut CP.

Ann Surg. 2017 Apr;265(4):814-820. doi: 10.1097/SLA.0000000000001753.

PMID:
28267696
13.

Incidence and Adverse Prognostic Implications of Histopathologic Organ Invasion in Primary Retroperitoneal Sarcoma.

Fairweather M, Wang J, Jo VY, Baldini EH, Bertagnolli MM, Raut CP.

J Am Coll Surg. 2017 May;224(5):876-883. doi: 10.1016/j.jamcollsurg.2017.01.044. Epub 2017 Jan 29.

PMID:
28147251
14.

Reply to L. Casadaban et al.

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2017 Apr 20;35(12):1373-1374. doi: 10.1200/JCO.2016.71.2646. Epub 2017 Jan 23. No abstract available.

PMID:
28113023
15.

A Study of Thymidylate Synthase Expression as a Biomarker for Resectable Colon Cancer: Alliance (Cancer and Leukemia Group B) 9581 and 89803.

Niedzwiecki D, Hasson RM, Lenz HJ, Ye C, Redston M, Ogino S, Fuchs CS, Compton CC, Mayer RJ, Goldberg RM, Colacchio TA, Saltz LB, Warren RS, Bertagnolli MM.

Oncologist. 2017 Jan;22(1):107-114. doi: 10.1634/theoncologist.2016-0215. Epub 2016 Nov 7.

16.

Bidirectional cross talk between patient-derived melanoma and cancer-associated fibroblasts promotes invasion and proliferation.

Izar B, Joyce CE, Goff S, Cho NL, Shah PM, Sharma G, Li J, Ibrahim N, Gold J, Hodi FS, Garraway LA, Novina CD, Bertagnolli MM, Yoon CH.

Pigment Cell Melanoma Res. 2016 Nov;29(6):656-668. doi: 10.1111/pcmr.12513. Epub 2016 Sep 22.

PMID:
27482935
17.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Jul 11;30(1):183. doi: 10.1016/j.ccell.2016.06.008. Epub 2016 Jul 11. No abstract available.

18.

Association Between Results of a Gene Expression Signature Assay and Recurrence-Free Interval in Patients With Stage II Colon Cancer in Cancer and Leukemia Group B 9581 (Alliance).

Niedzwiecki D, Frankel WL, Venook AP, Ye X, Friedman PN, Goldberg RM, Mayer RJ, Colacchio TA, Mulligan JM, Davison TS, O'Brien E, Kerr P, Johnston PG, Kennedy RD, Harkin DP, Schilsky RL, Bertagnolli MM, Warren RS, Innocenti F.

J Clin Oncol. 2016 Sep 1;34(25):3047-53. doi: 10.1200/JCO.2015.65.4699. Epub 2016 Jul 18.

19.

The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice.

Townsend EC, Murakami MA, Christodoulou A, Christie AL, Köster J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu SC, Plana O, Montero J, Stevenson KE, Rao P, Vadhi R, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorfman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf NR, LaCasce AS, Lees E, Li LS, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli MM, Ritz J, Brown M, Long H, Aster JC, Shipp MA, Griffin JD, Weinstock DM.

Cancer Cell. 2016 Apr 11;29(4):574-586. doi: 10.1016/j.ccell.2016.03.008. Erratum in: Cancer Cell. 2016 Jul 11;30(1):183.

20.

Systematic meta-analyses and field synopsis of genetic association studies in colorectal adenomas.

Montazeri Z, Theodoratou E, Nyiraneza C, Timofeeva M, Chen W, Svinti V, Sivakumaran S, Gresham G, Cubitt L, Carvajal-Carmona L, Bertagnolli MM, Zauber AG, Tomlinson I, Farrington SM, Dunlop MG, Campbell H, Little J.

Int J Epidemiol. 2016 Feb;45(1):186-205. doi: 10.1093/ije/dyv185. Epub 2015 Oct 7. Review.

21.

Accuracy of EUS and CT imaging in preoperative gastric cancer staging.

Fairweather M, Jajoo K, Sainani N, Bertagnolli MM, Wang J.

J Surg Oncol. 2015 Jun;111(8):1016-20. doi: 10.1002/jso.23919. Epub 2015 Apr 14.

PMID:
25872753
22.

Comparison of gastric cancer survival between Caucasian and Asian patients treated in the United States: results from the Surveillance Epidemiology and End Results (SEER) database.

Wang J, Sun Y, Bertagnolli MM.

Ann Surg Oncol. 2015 Sep;22(9):2965-71. doi: 10.1245/s10434-015-4388-4. Epub 2015 Jan 29.

PMID:
25631065
23.

Celecoxib inhibits early cutaneous wound healing.

Fairweather M, Heit YI, Buie J, Rosenberg LM, Briggs A, Orgill DP, Bertagnolli MM.

J Surg Res. 2015 Apr;194(2):717-24. doi: 10.1016/j.jss.2014.12.026. Epub 2014 Dec 18.

PMID:
25588948
24.

Antitumor effects of hyaluronan inhibition in desmoid tumors.

Briggs A, Rosenberg L, Buie JD, Rizvi H, Bertagnolli MM, Cho NL.

Carcinogenesis. 2015 Feb;36(2):272-9. doi: 10.1093/carcin/bgu324. Epub 2015 Jan 2.

PMID:
25556151
25.

Safety and efficacy of radiation dose delivered via iodine-125 brachytherapy mesh implantation for deep cavity sarcomas.

Fairweather M, Wang J, Devlin PM, Hansen J, Baldini EH, Ready JE, Sugarbaker DJ, Bertagnolli MM, Raut CP.

Ann Surg Oncol. 2015 May;22(5):1455-63. doi: 10.1245/s10434-014-4171-y. Epub 2014 Oct 24.

PMID:
25341749
26.
27.

MRE11-deficiency associated with improved long-term disease free survival and overall survival in a subset of stage III colon cancer patients in randomized CALGB 89803 trial.

Pavelitz T, Renfro L, Foster NR, Caracol A, Welsch P, Lao VV, Grady WB, Niedzwiecki D, Saltz LB, Bertagnolli MM, Goldberg RM, Rabinovitch PS, Emond M, Monnat RJ Jr, Maizels N.

PLoS One. 2014 Oct 13;9(10):e108483. doi: 10.1371/journal.pone.0108483. eCollection 2014.

28.

The 2010 Institute of Medicine consensus statement "A national clinical trials network for the 21st century": progress and challenges.

Mendelsohn J, Bertagnolli MM.

Semin Oncol. 2014 Aug;41(4):435-436. doi: 10.1053/j.seminoncol.2014.06.003. Epub 2014 Jun 11. No abstract available.

PMID:
25173135
29.

CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.

Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ, Maizels N, Niedzwiecki D, Goldberg RM, Saltz LB, Venook A, Warren RS, Grady WM; Alliance for Clinical Trials in Oncology.

Gastroenterology. 2014 Sep;147(3):637-45. doi: 10.1053/j.gastro.2014.05.009. Epub 2014 May 21.

30.

KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.

Serrano C, Wang Y, Mariño-Enríquez A, Lee JC, Ravegnini G, Morgan JA, Bertagnolli MM, Beadling C, Demetri GD, Corless CL, Heinrich MC, Fletcher JA.

J Clin Oncol. 2015 Aug 1;33(22):e93-6. doi: 10.1200/JCO.2013.48.7488. Epub 2014 Mar 31. No abstract available.

31.

Lack of anti-tumor activity with the β-catenin expression inhibitor EZN-3892 in the C57BL/6J Min/+ model of intestinal carcinogenesis.

Hasson RM, Briggs A, Rizvi H, Carothers AM, Davids JS, Bertagnolli MM, Cho NL.

Biochem Biophys Res Commun. 2014 Feb 14;444(3):283-9. doi: 10.1016/j.bbrc.2013.11.135. Epub 2014 Jan 31.

PMID:
24486542
32.

Desmoid-type fibromatosis and pregnancy: a multi-institutional analysis of recurrence and obstetric risk.

Fiore M, Coppola S, Cannell AJ, Colombo C, Bertagnolli MM, George S, Le Cesne A, Gladdy RA, Casali PG, Swallow CJ, Gronchi A, Bonvalot S, Raut CP.

Ann Surg. 2014 May;259(5):973-8. doi: 10.1097/SLA.0000000000000224.

PMID:
24477160
33.

Predictors of outcomes in patients with primary retroperitoneal dedifferentiated liposarcoma undergoing surgery.

Keung EZ, Hornick JL, Bertagnolli MM, Baldini EH, Raut CP.

J Am Coll Surg. 2014 Feb;218(2):206-17. doi: 10.1016/j.jamcollsurg.2013.10.009. Epub 2013 Oct 25.

PMID:
24315890
34.

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2013 Dec 4;105(23):1789-98. doi: 10.1093/jnci/djt298. Epub 2013 Nov 14.

35.

Estrogen receptor α or β loss in the colon of Min/+ mice promotes crypt expansion and impairs TGFβ and HNF3β signaling.

Hasson RM, Briggs A, Carothers AM, Davids JS, Wang J, Javid SH, Cho NL, Bertagnolli MM.

Carcinogenesis. 2014 Jan;35(1):96-102. doi: 10.1093/carcin/bgt323. Epub 2013 Oct 8.

36.

Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).

Nixon AB, Pang H, Starr MD, Friedman PN, Bertagnolli MM, Kindler HL, Goldberg RM, Venook AP, Hurwitz HI; Alliance for Clinical Trials In Oncology.

Clin Cancer Res. 2013 Dec 15;19(24):6957-66. doi: 10.1158/1078-0432.CCR-13-0926. Epub 2013 Oct 4.

37.

Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.

Wang J, Carvajal-Carmona LG, Chu JH, Zauber AG; APC Trial Collaborators, Kubo M, Matsuda K, Dunlop M, Houlston RS, Sieber O, Lipton L, Gibbs P, Martin NG, Montgomery GW, Young J, Baird PN, Ratain MJ, Nakamura Y, Weiss ST, Tomlinson I, Bertagnolli MM.

Clin Cancer Res. 2013 Dec 1;19(23):6430-7. doi: 10.1158/1078-0432.CCR-13-0550. Epub 2013 Oct 1.

38.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.

J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.

39.

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Warren RS, Atreya CE, Niedzwiecki D, Weinberg VK, Donner DB, Mayer RJ, Goldberg RM, Compton CC, Zuraek MB, Ye C, Saltz LB, Bertagnolli MM.

Clin Cancer Res. 2013 Oct 15;19(20):5777-87. doi: 10.1158/1078-0432.CCR-13-0351. Epub 2013 Aug 27.

40.

Biologic determinants of tumor recurrence in stage II colon cancer: validation study of the 12-gene recurrence score in cancer and leukemia group B (CALGB) 9581.

Venook AP, Niedzwiecki D, Lopatin M, Ye X, Lee M, Friedman PN, Frankel W, Clark-Langone K, Millward C, Shak S, Goldberg RM, Mahmoud NN, Warren RS, Schilsky RL, Bertagnolli MM.

J Clin Oncol. 2013 May 10;31(14):1775-81. doi: 10.1200/JCO.2012.45.1096. Epub 2013 Mar 25.

41.

Predictors for major wound complications following preoperative radiotherapy and surgery for soft-tissue sarcoma of the extremities and trunk: importance of tumor proximity to skin surface.

Baldini EH, Lapidus MR, Wang Q, Manola J, Orgill DP, Pomahac B, Marcus KJ, Bertagnolli MM, Devlin PM, George S, Abraham J, Ferrone ML, Ready JE, Raut CP.

Ann Surg Oncol. 2013 May;20(5):1494-9. doi: 10.1245/s10434-012-2797-1. Epub 2012 Dec 15.

PMID:
23242820
42.

Much of the genetic risk of colorectal cancer is likely to be mediated through susceptibility to adenomas.

Carvajal-Carmona LG, Zauber AG, Jones AM, Howarth K, Wang J, Cheng T; APC Trial Collaborators; APPROVe Trial Collaborators; CORGI Study Collaborators; Colon Cancer Family Registry Collaborators; CGEMS Collaborators, Riddell R, Lanas A, Morton D, Bertagnolli MM, Tomlinson I.

Gastroenterology. 2013 Jan;144(1):53-5. doi: 10.1053/j.gastro.2012.09.016. Epub 2012 Sep 19.

43.

Ethical aspects of participation in the database of genotypes and phenotypes of the National Center for Biotechnology Information: the Cancer and Leukemia Group B Experience.

Peppercorn J, Shapira I, Deshields T, Kroetz D, Friedman P, Spears P, Collyar DE, Shulman LN, Dressler L, Bertagnolli MM.

Cancer. 2012 Oct 15;118(20):5060-8. doi: 10.1002/cncr.27515. Epub 2012 Mar 13.

44.

The APC and PreSAP trials: a post hoc noninferiority analysis using a comprehensive new measure for gastrointestinal tract injury in 2 randomized, double-blind studies comparing celecoxib and placebo.

Arber N, Lieberman D, Wang TC, Zhang R, Sands GH, Bertagnolli MM, Hawk ET, Eagle C, Coindreau J, Zauber A, Lanas A, Levin B.

Clin Ther. 2012 Mar;34(3):569-79. doi: 10.1016/j.clinthera.2012.02.001. Epub 2012 Mar 2.

PMID:
22386831
45.

Celecoxib pathways: pharmacokinetics and pharmacodynamics.

Gong L, Thorn CF, Bertagnolli MM, Grosser T, Altman RB, Klein TE.

Pharmacogenet Genomics. 2012 Apr;22(4):310-8. doi: 10.1097/FPC.0b013e32834f94cb. No abstract available.

46.

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.

Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6.

47.

Mesenchymal stromal cell mutations and wound healing contribute to the etiology of desmoid tumors.

Carothers AM, Rizvi H, Hasson RM, Heit YI, Davids JS, Bertagnolli MM, Cho NL.

Cancer Res. 2012 Jan 1;72(1):346-55. doi: 10.1158/0008-5472.CAN-11-2819. Epub 2011 Nov 17.

48.

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma.

Chan AT, Hsu M, Zauber AG, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2012 Jan;5(1):61-72. doi: 10.1158/1940-6207.CAPR-11-0337. Epub 2011 Oct 26.

49.

Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

Ng K, Ogino S, Meyerhardt JA, Chan JA, Chan AT, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, Benson AB 3rd, Schaefer PL, Whittom R, Hantel A, Goldberg RM, Bertagnolli MM, Venook AP, Fuchs CS.

J Natl Cancer Inst. 2011 Oct 19;103(20):1540-51. doi: 10.1093/jnci/djr307. Epub 2011 Aug 17.

50.

C-reactive protein and risk of colorectal adenoma according to celecoxib treatment.

Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM.

Cancer Prev Res (Phila). 2011 Aug;4(8):1172-80. doi: 10.1158/1940-6207.CAPR-10-0403.

Supplemental Content

Loading ...
Support Center